Ultrasound-assisted CNSs Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy (UltraCars)
Ultrasound-assisted Carbon Nanoparticle Suspensions Mapping Versus Dual-tracer-guided Sentinel Lymph Node Biopsy in Patients With Early Breast Cancer (UltraCars): a Prospective, Randomized Controlled Phase 3 Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Guangzhou, China
- Guangdong General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- The participants must be female and 18 years of age or older.
- Resectable invasive adenocarcinoma of the breast, confirmed histologically.
- Ductal carcinoma in situ confirmed histologically.
- The participants must be a preoperative clinical Tis, T1, T2, T3 as well as clinical M0 breast cancer.
- Without clinical or radiological nodal involvement (cN0): No positive ipsilateral axillary lymph nodes; No prior removal of ipsilateral axillary lymph nodes; No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy.
- With clinical positive lymph nodes (cN1) (including any abnormal or enlarged clinically palpable lymph nodes or core biopsy/surgical biopsy/FNA evidence of malignant cell within any lymph nodes) that was downstaged to cN0 following neoadjuvant therapy.
- The participants must have an ECOG performance status of Grade 0-1.
- The participants must provide written informed consent before participating in the study.
Exclusion criteria:
- The breast has ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude. Tethering or dimpling of the skin or nipple inversion allowed.
- The participants has a known hypersensitivity to tracers planned for use during SLNB.
- Other prior breast malignancy except lobular carcinoma in situ.
- The participants has had prior breast implants.
- The participants has had prior breast reduction surgery.
- The participants has had other prior surgery in the upper, outer quadrant, areola, or axilla to the indicated breast.
- The participants has a positive pregnancy test or is lactating.
- The participants has participated in another investigational drug study during the 30 days prior to signing informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: UC group
Ultrasound-assisted CNSs guided SLN mapping
|
1ml of CNSs was subcutaneously injected into the areolar area in the upper outer quadrant of the breast.
The injection site was massaged for 15 minutes to promote drainage of the tracer to the axilla.
During the intraoperative ultrasound-assisted procedure, an ultrasound diagnostic system was used.
Before the incision, ultrasound-guided exploration of SLNs was performed by placing the probe on the lateral border of the breast and sliding cranially along the lateral border of the pectoralis major muscle .
A sterile skin marker was then used to mark the optimal site of incision over the targeted lymph nodes, and the distance from the skin to the nodes was measured by ultrasound and recorded in millimeters.
Blunt dissection was carried out to identify the CNSs-stained nodes around the marked region.
Ultrasonography probe was placed repeatedly in or around the wound at different angles for adequate visualization if SLNs could not be localized with further dissection.
|
|
ACTIVE_COMPARATOR: GC group
CNSs plus ICG dual-tracer-guided SLN mapping
|
The preparation of CNSs mapping was identical to that of the UC group.
1ml of diluted ICG was subsequently injected into the areolar area in the upper outer quadrant of the breast.
A NIR camera was used to visualize the subcutaneous lymph vessels and localized the SLNs.
All fluorescent or black-stained lymph nodes along with any palpable suspicious nodes were removed.
The remaining surgical field was reexamined to ensure complete resection of fluorescent lymph nodes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The identification rate of SLNs
Time Frame: within 14 days of SLNB
|
Defined as the number of patients who at least one SLN were detected divided by the total number of patients included.
|
within 14 days of SLNB
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The mean number of SLNs collected
Time Frame: within 14 days of SLNB
|
Defined as the number of tracer-stained or palpable SLNs divided by the number of patients whose SLNs were identified.
|
within 14 days of SLNB
|
|
Operative time
Time Frame: within 14 days of SLNB
|
Defined as the time from skin incision to resection of the SLNs specimens in patients whose at least one SLN were detected.
|
within 14 days of SLNB
|
|
Intraoperative or postoperative complications
Time Frame: within 30 days of SLNB
|
An adverse event is any untoward, undesired, and/or unplanned clinical event in the form of signs, symptoms, disease, or laboratory testing, or physiological observations occurring in a human participating in a clinical study with a study drug, regardless of causal relationship.
|
within 30 days of SLNB
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Identification rate of SLNs in post-NCT patients
Time Frame: within 14 days of SLNB
|
Defined as the number of patients who at least one SLN were detected divided by the total number of patients included in NCT subgroup.
|
within 14 days of SLNB
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Kun Wang, MD, Guangdong Provincial People's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20190511
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.